A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children

Journal of Clinical Investigation

Volumn 105, Issue 7, 2000, Pages 995-1003

  Persaud, Deborah ^a   Pierson, Theodore ^a   Ruff, Christian ^a   Finzi, Diana ^a   Chadwick, Karen R ^b   Margolick, Joseph B ^b   Ruff, Andrea ^a   Hutton, Nancy ^a   Ray, Stuart ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CLINICAL ARTICLE; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS ISOLATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0034076571     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9006     Document Type: Article

References (41)

1. Finzi, D., and Siliciano, R.F. 1998. Viral dynamics in HIV-1 infection. Cell. 93:665-671.
2. Zack, J.A., et al. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61:213-222.
3. Chun, T.W., et al. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1:1284-1290.
4. Bukrinsky, M.I., et al. 1992. Active nuclear import of human immunodeficiency virus type 1 pre-integration complexes. Proc. Natl. Acad. Sci. USA. 89:6580-6584.
5. Ho, D.D., et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:123-126.
6. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard J.M., and Ho, D.D. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1582-1586.
7. Wei, X., et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:117-122.
8. Melvin, A.J., et al. 1999. HIV-1 dynamics in children. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:468-473.
9. Luzuriaga, K., et al. 1999. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J. Virol. 73:362-367.
10. Perelson, A.S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387:188-191.
11. Cavert, W., et al. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 276:960-964.
12. Finzi, D., et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-1300.
13. Chun, T.W., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 94:13193-13197.
14. Wong, J.K., et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1291-1295.
15. McLean, A.R., and Michie, C.A. 1995. In vivo estimates of division and death rates of human T lymphocytes. Proc. Natl. Acad. Sci. USA, 92:3707-3711.
16. Michie, C.A., McLean, A., Alcock, C., and Beverley, P.C. 1992. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 360:264-265.
17. Mofenson, L.M., et al. 1997. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J. Infect. Dis. 175:1029-1038.
18. Palumbo, P.E.,et al. 1995. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J. Pediatr. 126:592-595.
19. Shearer, W.T., et al. 1997. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336:1337-1342.
20. Pikora, C.A., Sullivan, J.L., Panicali, D., and Luzuriaga, K. 1997. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J. Exp. Med. 185:1153-1161.
21. Luzuriaga, K., Koup, R.A., Pikora, C.A., Brettler, D.B., and Sullivan, J.L. 1991. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J. Pediatr. 119:230-236.
22. Luzuriaga, K., et al. 1995. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J. Immunol. 154:433-443.
23. Chun, T.W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:183-188.
24. Hayward, A.R., Lee, J., and Beverley, P.C.L. 1989. Ontogeny of expression of UCHL1 antigen on TcR1+ (CD4/8) and TcRd+ cells. Eur. J. Immunol. 18:1653-1661.
25. Myers, L.E., McQuay, L.J., and Hollinger, F.B. 1994. Dilution assay statistics. J. Clin. Microbiol. 32:732-739.
26. Richman, D.D., Guatelli, J.C., Grimes, J., Tsiatis, A., and Gingeras, T. 1991. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of polymerase chain reaction. J. Infeit. Dis. 164:1075-1081.
27. Hertogs, K., et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
28. Learn, G.H., Jr., et al. 1996. Maintaining the integrity of human immunodeficiency virus sequence databases. J. Virol. 70:5720-5730.
29. Hammond, J., Calef, C., Larder, B., Schinazi, R., and Mellors, J.W. 1998. Mutations in retroviral genes associated with drug resistance. In Human retroviruses and AIDS 1998: a compilation and analysis of nucleic acid and amino acid sequences. B.T. Korber et al., editors. Los Alamos National Laboratory. Los Alamos, NM. pp. III-36-III-79.
30. Nei, M., and Gojobori, T. 1996. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3:418-426.
31. Felsenstein, J. 1999. PHYLIP(Phylogeny Inference Package). Version 3.572c. Department of Genetics, University of Washington, Seattle, WA.
32. 1994. Revised classification system for human immunodeficiency virus in children less than 13 years of age. MMWR Morb. Mort. Wkly. Rep. 43(RR-12):1-10.
33. Bukrinsky, M.I., Stanwick, T.I., Dempsey, M.P, and Stevenson, M. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 254:423-427.
34. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
35. Furtado, M.R., et al. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl J. Med. 340:1614-1622.
36. Grossman, Z., et al. 1999. Ongoing HIV dissemination during HAART. Nat. Med. 5:1099-1104.
37. Zhang, L., et al. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
38. Dornadula, G., et al. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 282:1627-1632.
39. Larder, B.A., et al. 1999 A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1961-1967.
40. Ross, L., Johnson, M., Graham, N., Shaefer, M, and St. Clair, M. 1999. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. J. Hum. Virol. 2:290-295.
41. Winters, M.A., et al. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 102:1769-1775.